BioVersys AG | Finanzwire

Basculer en Français

9526	Companies
187402	Keywords
119432	Articles
100169	Press releases

Home
Companies
BioVersys AG

BRIEF

published on 12/11/2025 at 07:05, 4 days 8 hours ago

BioVersys Initiates Phase 3 Trial for BV100 and Updates Business Progress

IPO Drug Resistance BioVersys BV100 Phase 3 Antibacterial Research
PRESS RELEASE

published on 12/11/2025 at 07:00, 4 days 8 hours ago

BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update
BioVersys AG initiates BV100 Phase 3 study for ventilator-associated bacterial pneumonia, achieving significant milestones in 2025 and upcoming key events in 2026

Clinical Trials Biopharmaceutical BioVersys AG BV100 Phase 3 Ventilator Associated Bacterial Pneumonia
BRIEF

published on 11/10/2025 at 07:05, 1 month 5 days ago

BioVersys' BV100 Phase 2B Study Set for Asia

Phase 2B Trial Drug Resistance BioVersys BV100 Wellcome Funding ADVANCE-ID Network
PRESS RELEASE

published on 11/10/2025 at 07:00, 1 month 5 days ago

BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network
BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network. BioVersys AG leads Phase 2 trial for innovative antibacterial product BV100

Phase 2b Clinical Trial BV100 BioVersys Wellcome Funded Trial Network
BRIEF

published on 11/06/2025 at 07:05, 1 month 9 days ago

BioVersys Advances BV100 Clinical Trials in China

Clinical Trials BV100 BioVersys MDR Bacteria Acinetobacter
PRESS RELEASE

published on 11/06/2025 at 07:00, 1 month 9 days ago

Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA
BioVersys announces the dosing of the first subject in a Phase 1 clinical trial with BV100 in China. BV100 targets MDR hospital infections caused by Acinetobacter baumannii

Phase 1 Clinical Trial BV100 BioVersys MDR Bacteria Acinetobacter Baumannii
BRIEF

published on 11/05/2025 at 07:05, 1 month 10 days ago

BioVersys to Present at Stifel 2025 Annual Healthcare Conference

New York City Healthcare Conference Clinical Developments BioVersys Multi-drug Resistant Bacteria
PRESS RELEASE

published on 11/05/2025 at 07:00, 1 month 10 days ago

Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york
BioVersys AG will present at Stifel 2025 Annual Healthcare Conference in New York, showcasing latest clinical and preclinical developments. Key focus on antibacterial products for MDR bacteria

Healthcare Conference BioVersys AG Antibacterial Products MDR Bacteria Stifel 2025
BRIEF

published on 11/03/2025 at 07:05, 1 month 12 days ago

BioVersys Appoints Dr. Daniel Ritz as Chief Scientific Officer

Chief Scientific Officer BioVersys MDR Bacteria Dr. Daniel Ritz Anti-infective
PRESS RELEASE

published on 11/03/2025 at 07:00, 1 month 12 days ago

Bioversys announces appointment of anti-infective expert Dr. Daniel Ritz as Chief Scientific Officer and retirement of Dr. Sergio Lociuro
BioVersys appoints Dr. Daniel Ritz as CSO and announces retirement of Dr. Sergio Lociuro. Dr. Ritz brings expertise in anti-infectives with track record in antibiotic compounds

CSO BioVersys Dr. Daniel Ritz Anti-infectives Antibiotic Compounds

1 2 ... 5

Accesswire

Published on 12/15/2025 at 15:00, 39 minutes ago

Kingfisher Reports Annual General Meeting Voting Results
Published on 12/15/2025 at 15:00, 39 minutes ago

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Published on 12/15/2025 at 14:30, 1 hour 9 minutes ago

Unusual Machines Congratulates Customers Selected for the Army's PBAS Tranche 1.1, Including Envision Technology and Strategic Logix
Published on 12/15/2025 at 14:00, 1 hour 39 minutes ago

Dateline Delivers Further High-Grade Intercepts from North Pipe at Colosseum
Published on 12/15/2025 at 13:30, 2 hours 9 minutes ago

Greenlane Announces Results of Annual Meeting of Stockholders, Canopy Growth Co Founder Bruce Linton Joins Greenlane's Board of Directors

View all ACCESSWIRE

EQS Group

Published on 12/15/2025 at 15:14, 24 minutes ago

Edison issues report on Aberdeen Asian Income Fund (AAIF)
Published on 12/15/2025 at 15:00, 38 minutes ago

Partners Group’s announcement of AuM as of 31 December 2025
Published on 12/15/2025 at 14:56, 42 minutes ago

EQS-Adhoc: Wolford AG: Mandate of Ralf Polito as Member of the Management Board extended
Published on 12/15/2025 at 14:43, 55 minutes ago

Bilfinger SE: Share Buyback
Published on 12/15/2025 at 13:35, 2 hours 3 minutes ago

DeFi Technologies Announces Launch of Brazilian Depositary Receipts for Institutional Investors on B3 Exchange

Les Echos

Published on 12/15/2025 at 11:50, 3 hours 48 minutes ago

Statement about the number of shares composing the share capital and the number of voting rights as of November 30, 2025
Published on 12/12/2025 at 18:00, 2 days 21 hours ago

Disclosure of trading in own shares between November 24th and November 28th, 2025
Published on 12/12/2025 at 09:15, 3 days 6 hours ago

CHANGE IN THE SHARE CAPITAL
Published on 12/11/2025 at 19:23, 3 days 20 hours ago

Eiffage is joining the CAC 40 index
Published on 12/11/2025 at 08:30, 4 days 7 hours ago

Edenred and Daimler Truck join forces to accelerate the rollout of charging infrastructure for electric trucks in Europe

View all LES ECHOS COMFI WIRE